PCN121 LONG-TERM COST-EFFECTIVENESS MODELING COMPARING MATURITY OF DATA CUTS: A COMPARISON BETWEEN COST-EFFECTIVENESS OF NIVOLUMAB VS EVEROLIMUS IN SECOND LINE RENAL CELL CARCINOMA USING 2- OR 3-YEAR FOLLOW UP CHECKMATE-025 DATA

Autor:	H. Sandhu, A. Berardi
Rok vydání:	2020
Předmět:	Oncology medicine.medical_specialty Everolimus Cost effectiveness business.industry Health Policy Public Health Environmental and Occupational Health Checkmate medicine.disease Maturity (finance) Term (time) Second line Renal cell carcinoma Internal medicine medicine Nivolumab business medicine.drug
Zdroj:	Value in Health. 23:S44
ISSN:	1098-3015
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::a2066e39a14b10f6a6b79e56c6007384 https://doi.org/10.1016/j.jval.2020.04.1612 Zobrazit plný text záznamu Full Text from ScienceDirect